A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 4, 2014, Pages 419-423

  Estébanez, Miriam ^a   Stella Ascariz, Natalia ^a   Mingorance, Jesús ^a   Pérez Valero, Ignacio ^a   González Baeza, Alicia ^a   Bayón, Carmen ^a   Lakatos, Botond ^a,b   Borobia, Alberto ^a   Arnalich, Francisco ^a   Arribas, José R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cerebrospinal fluid; Darunavir; HIV; Lopinavir; Monotherapy; Neurocognitive impairment; Viral escape

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENOLASE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MYELIN BASIC PROTEIN; PROTEIN S100B; PROTEINASE INHIBITOR; TAU PROTEIN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; SULFONAMIDE;

ADULT; ATTENTION; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LEARNING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR PERFORMANCE; PRIORITY JOURNAL; VIRUS LOAD; WORKING MEMORY; AIDS DEMENTIA COMPLEX; COMPARATIVE STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SULFONAMIDES; VIRAL LOAD;

EID: 84922480865     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000337     Document Type: Conference Paper

References (14)

1. Perez-Valero I, Bayon C, Cambron I, et al. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother. 2011;66: 1954-1962.
2. Clifford DB. Therapeutic conundrum: AIDS therapies may be doubleedged swords. Neurology. 2010;74:1248-1249.
3. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388-399.
4. Bunupuradah T, Chetchotisakd P, Jirajariyavej S, et al. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavirbased antiretroviral therapy vs. lopinavir/ritonavir monotherapy. J Neurovirol. 2012;18:479-487.
5. Santos JR, Muñoz-Moreno JA, Moltó J, et al. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS One. 2013;8:e70201.
6. Pasquier Du RA, Jilek S, Kalubi M, et al. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS. 2013;27:203-210.
7. Pérez-Valero I, Gonzalez-Baeza A, Estébanez M, et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One. 2013;8:e69493.
8. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799.
9. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307-319.
10. Yilmaz A, Verhofstede C, D'Avolio A, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2010; 55:590-596.
11. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204: 1936-1945.
12. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatmentexperienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406-413.
13. Letendre S, McClernon D, Ellis R, et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 484b.
14. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry. 2008;20:73-88.